Clin Osteol 2024; 29(4): 136-142

What's (new) in the guidelines of the osteological societies of the German-speaking countries published in 2023Comments

Hess Zdeněk1,2
1 Fakulta zdravotnických studií Západočeské univerzity v Plzni
2 Ordinace všeobecného praktického lékařství, s. r. o., Mariánské Lázně

The 2023 guidelines from German-speaking scientific osteological societies offer updated recommendations for osteoporosis prevention, diagnosis, and treatment, focusing on new risk factors, such as humeral fractures, cardiac and renal insufficiency, and chronic hyponatremia. The guidelines also consider additional factors, like immobility and HIV, and newly define bone density thresholds for initiating treatment. Romosozumab has been added as a therapeutic option to reduce the risk of vertebral and non-vertebral fractures. The improved fracture risk calculator now combines the two strongest risk factors with bone density measurements and shortens the predictive period to 3 years. The recommendations also include daily doses of vitamins D and K2, along with guidance for physiotherapy, rehabilitation, and managed care programs.

Keywords: 2023 guidelines; new risk factors; osteoporosis; romosozumab; updated recommen-dations for osteoporosis prevention, diagnosis, treatment

Published: December 11, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hess Z. What's (new) in the guidelines of the osteological societies of the German-speaking countries published in 2023. Clinical Osteology. 2024;29(4):136-142.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Leslie WD, Berger C, Langsetmo L et al. [Canadian Multicentre Osteoporosis Study (CaMos) Research Group]. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 2011; 22(6): 1873-1883. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-010-1445-5>. Go to original source...
    2. Bilezikian JP, Formenti AM, Adler RA et al. Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all? Rev Endocr Metab Disord 2021; 22(4): 1201-1218. Dostupné z DOI: <http://dx.doi.org/10.1007/s11154-021-09693-7>. Go to original source...
    3. Sanders KM, Stuart AL, Williamson EJ et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303(18): 1815-1822. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2010.594>. Go to original source...
    4. Smith H, Anderson F, Raphael H et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2007; 46(12): 1852-1857. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kem240>. Go to original source...
    5. Bischoff-Ferrari HA, Freystätter G, Vellas B et al. [DO-HEALTH Research Group]. Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. Am J Clin Nutr 2022; 115(5): 1311-1321. Dostupné z DOI: <http://dx.doi.org/10.1093/ajcn/nqac022>. Go to original source...
    6. Dai Z, McKenzie JE McDonald S et al. Assessment of the Methods Used to Develop Vitamin D and Calcium Recommendations-A Systematic Review of Bone Health Guidelines. Nutrients 2021; 13(7): 2423. Dostupné z DOI: <http://dx.doi.org/10.3390/nu13072423>. Go to original source...
    7. Kimball SM, Holick MF. Official recommendations for vitamin D through the life stages in developed countries. Eur J Clin Nutr 2020; 74(11): 1514-1518. Dostupné z DOI: <http://dx.doi.org/10.1038/s41430-020-00706-3>. Go to original source...
    8. Simes DC, Viegas CS, Araujo N et al. Vitamin K as a Diet Supplement with Impact in Human Health: Current Evidence in Age-Related Diseases. Nutrients 2020; 12(1): 138. Dostupné z DOI: <http://dx.doi.org/10.3390/nu12010138>. Go to original source...
    9. Mladenka P Macakova K, Kujovska Krcmova L et al. Vitamin K -⁠ sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev 2022; 80(4): 677-698. Dostupné z DOI: <http://dx.doi.org/10.1093/nutrit/nuab061>. Go to original source...
    10. Riphagen LJ, Keyzer CA, Drummen NE et al. Prevalence and Effects of Functional Vitamin K Insufficiency: The PREVEND Study. Nutrients 2017; 9(12): 1334. Dostupné z DOI: <http://dx.doi.org/10.3390/nu9121334>. Go to original source...
    11. Saag KG, Petersen J, Brandi ML et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377(15): 1417-1427. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1708322>. Go to original source...
    12. Kendler DL, Marin F, Zerbini CA et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double dummy, randomised controlled trial. Lancet 2018; 391(10117): 230-240. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(17)32137-2>. Erratum in: Lancet 2018; 392(10162): 2352. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(18)32944-1>. Go to original source...
    13. Gnant M, Pfeiler G, Dubsky PC et al. [Austrian Breast and Colorectal Cancer Study Group]. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386(9992): 433-443. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(15)60995-3>. Go to original source...
    14. Abdel-Rahman O. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis. Expert Rev Anticancer Ther 2016; 16(8): 885-891. Dostupné z DOI: <http://dx.doi.org/10.1080/14737140.2016.1192466>. Go to original source...
    15. Coleman R, Hadji P, Body JJ et al. [ESMO Guidelines Committee]. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020; 31(12): 1650-1663. Dostupné z DOI: <http://dx.doi.org/10.1016/j.annonc.2020.07.019>. Go to original source...
    16. Smith MR, Egerdie B, Hernández Toriz N et al. [Denosumab HALT Prostate Cancer Study Group]. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361(8): 745-755. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0809003>. Go to original source...
    17. Alibhai SM, Zukotynski K, Walker-Dilks C et al. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 167(5): 341-350. Dostupné z DOI: <http://dx.doi.org/10.7326/M16-2577>. Go to original source...
    18. Poon Y, Pechlivanoglou P, Alibhai SM et al. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 2018; 121(1): 17-28. Dostupné z DOI: <http://dx.doi.org/10.1111/bju.14015>. Go to original source...
    19. Handoll HH, Cameron ID, Mak JC et al. Multidisciplinary rehabilitation for older people with hip fractures. Cochrane Database Syst Rev 2021; 11(11): CD007125. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD007125.pub3>. Go to original source...
    20. Smith TO, Gilbert AW, Sreekanta A et al. Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery. Cochrane Database Syst Rev 2020; 2(2): CD010569. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD010569.pub3>. Go to original source...
    21. Talevski J, Sanders KM, Duque G et al. Effect of Clinical Care Pathways on Quality of Life and Physical Function After Fragility Fracture: A Meta-analysis. J Am Med Dir Asso 2019; 20(7): 926.e1-926.e11. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jamda.2019.02.022>. Go to original source...
    22. Martineau AR, Jolliffe DA, Hooper R et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.i6583>. Go to original source...
    23. Andresen C, Olson E, Nduaka CI et al. Action of calciotropic hormones on bone metabolism: role of vitamin D3 in bone remodeling events. Am J Immunol 2006; 2(2): 40-51. Dostupné z DOI: <https://doi.org/10.3844/ajisp.2006.40.51>. Go to original source...
    24. Manson JE, Cook NR, Lee IM et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019; 380(1): 33-44. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1809944>. Go to original source...
    25. Gillespie LD, Robertson MC, Gillespie WJ et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012; 2012(9): CD007146. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD007146.pub3>. Go to original source...
    26. Saag KG, Pannacciulli N, Geusens P et al. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis Rheumatol 2019; 71(7): 1174-1184. Dostupné z DOI: <http://dx.doi.org/10.1002/art.40874>. Go to original source...
    27. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20): 2028-2039. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa071408>. Go to original source...
    28. Saag KG, Wagman RB, Geusens P et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 2018; 6(6): 445-454. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213-8587(18)30075-5>. Go to original source...
    29. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60(11): 3346-3355. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24879>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.